BMGF – Gates Foundation [to 21 April 2018]
APRIL 13, 2018
Bill & Melinda Gates Foundation Appoints Amy Pollack as Director of Maternal, Newborn & Child Health
SEATTLE, April 13, 2018 – The Bill & Melinda Gates Foundation today announced that Amy Pollack, MD, FACOG, FACPM has been named director of Maternal, Newborn & Child Health. She will assume her position on May 7, 2018.
Pollack joins the foundation from Medtronic, where she most recently served as the Chief Safety Officer and set the strategy and policy for medical safety across the company’s global business groups. Pollack has more than 25 years of experience in domestic and international health, including work in clinical practice; as the CEO of an international women’s health non-profit; and as an executive in early-stage medical device businesses, social venture capital, and industry. She has led global health multilateral negotiations for disruptive technologies, and she led national working groups in U.S. government policy change around the HPV vaccine, cervical cytology, and prostate cancer. Pollack is board certified in Obstetrics and Gynecology and Preventive Medicine.
“Amy brings deep experience in domestic and global health, strategy development, and in leading high-performing teams of technical experts,” said Chris Elias, president, Global Development at the Bill & Melinda Gates Foundation. “She will play a central role in the foundation’s efforts to save the lives of women, newborns, and children around the world.”…
FDA [to 21 April 2018]
April 17, 2018 –
Statement from FDA Commissioner Scott Gottlieb, M.D., on new efforts to enhance and modernize the FDA’s approach to medical device safety and innovation
Fondation Merieux [to 21 April 2018]
April 20, 2018
The Mérieux Foundation presents the results of two studies on pneumonia at the European Congress ECCMID 2018
The Mérieux Foundation is participating in the 28th European Congress of Clinical Microbiology and Infectious Diseases, held in Madrid, Spain from April 21-24. During this European congress devoted to microbiology and infectious diseases, the Foundation has two oral presentations and three posters.
Gavi [to 21 April 2018]
18 April 2018
United Arab Emirates to host Gavi 2018 mid-term review
The high-level event will celebrate 10 million lives saved since Gavi’s inception, launching its next replenishment cycle.
Abu Dhabi/Geneva, 18 April 2018 – The Minister of State for International Cooperation for the United Arab Emirates (UAE) HE Reem Al Hashimy announced today that the UAE will host the Gavi 2018 mid–term review.
The high-level conference will take place in Abu Dhabi on 10-11 December 2018 and will lay out a vision for the future of the Gavi model, providing an opportunity to take stock of Gavi’s performance halfway through the current strategic period (2016-2020). The conference will outline new ways of working with partners, allowing Gavi to forge new alliances with the private sector and adopt transformative solutions to advance the global immunisation agenda…
Global Fund [to 21 April 2018]
18 April 2018
Global Fund Joins Movement to Halve Malaria by 2023
The Global Fund today joins leaders meeting at the Malaria Summit London 2018 in a call to reduce malaria by one half across the Commonwealth in the next five years. Such collective actions aims to prevent 350 million cases of malaria and save 650,000 lives, predominately children and pregnant women.
[See Milestones above for more detail]
Global Fund Applauds UK’s Leadership in Fight Against Malaria
17 April 2018
Today the United Kingdom’s International Development Secretary Penny Mordaunt announced a £100 million fund to fight malaria to be matched by the private sector, which will be used to support priority countries with mosquito nets, indoor sprays and the strengthening of health systems.
NIH [to 21 April 2018]
April 16, 2018
Genetically altered broadly neutralizing antibodies protect monkeys from HIV-like virus
— NIH scientists report single dose elicited long-term protection.
PATH [to 21 April 2018]
Press release | April 17, 2018
PATH and Mologic advance a new diagnostic test to support malaria elimination
Test will expand the range of diagnostic options available to guide treatment of Plasmodium vivax
UNAIDS [to 21 April 2018]
20 April 2018
An historic opportunity to end AIDS in Africa
A new report released by UNAIDS shows that ending the AIDS epidemic in Africa can be reached if investments are secured and plans are in place for long-term sustainability.
The report, Turning point for Africa: An historic opportunity to end AIDS as a public health threat by 2030 and launch a new era of sustainability recommends developing country-tailored sustainability plans to enable transition towards domestic ownership and financing at each country’s own pace. It also highlights that sustainable progress will require changing policies, increasing human resources for health, increasing efficiencies and addressing systemic inequalities.
The Executive Director of UNAIDS Michel Sidibé presented the new report to African Ministers of Finance, multilateral partners and other senior officials at a meeting on optimizing investments and partnerships to end AIDS in Africa organized by the United States Department of Treasury and the United States President’s Emergency Plan for AIDS Relief (PEPFAR).
VI Eastern Europe and Central Asia Conference on HIV/AIDS opens in Moscow
20 April 2018
A record 3000 delegates from more than sixty countries, including representatives of civil society, scientific institutions, the private sector and governments, gathered in Moscow from 18 to 20 April 2018 to participate in the sixth Eastern Europe and Central Asia Conference on HIV/AIDS. The conference focused on four major tracks: prevention, science and treatment, civil society, and international cooperation.
Eastern Europe and Central Asia is the only region where the number of new HIV infections and AIDS-related death are still on the rise. The conference provides a unique opportunity to take stock of progress and discuss the challenges and transformation needed to get the Eastern Europe and Central Asia region on track to end AIDS…
UNICEF [to 21 April 2018]
Selected Press Releases
17 April 2018
Military action on and around water infrastructure jeopardizes efforts to prevent another outbreak of cholera in Yemen
AMMAN, 17 April 2018 – “Yemen continues to be one of the world’s most water-scarce countries. Access to drinking water is extremely costly for the most vulnerable people: 8.6 million children in Yemen don’t have sufficient access to water, sanitation and hygiene services.
[See Emergencies above for more detail]
The Wistar Institute [to 21 April 2018]
Press Release Apr. 19 2018
Wistar Team Receives Prestigious Award from National Clinical Research Forum for DNA-based Zika Research
The Wistar Institute and partners at the Perelman School of Medicine at the University of Pennsylvania, Inovio Pharmaceuticals, and GeneOne Life Science were recognized among the Top 10 Clinical Research Achievement Awards by the Clinical Research Forum for their ground-breaking phase 1 DNA-based Zika vaccine research – the first trial of a Zika vaccine in humans, which proved safe and effective. These study results were published in October in the New England Journal of Medicine…
Coalition for Epidemic Preparedness Innovations Supports MERS & Lassa Enhanced DNA Vaccine Technology to Expedite Vaccine Development
PHILADELPHIA — (April 19, 2018) — The Wistar Institute and Inovio Pharmaceuticals, Inc. are leading the charge to rapidly advance a Middle East Respiratory Syndrome (MERS) vaccine through phase II development as part of an innovative partnership with the Coalition for Epidemic Preparedness Innovations (CEPI). CEPI, which launched last year, aims to derail epidemics by speeding up the development of vaccines.
CEPI will fund nearly $56 million to support pre-clinical and clinical research of Inovio’s Lassa fever vaccine and to further develop a MERS DNA vaccine based on key technology generated in the lab of David B. Weiner, Ph.D., executive vice president, director of the Vaccine & Immunotherapy Center, and the W.W. Smith Endowed Chair in Cancer Research at The Wistar Institute. Wistar is a sub-awardee and will receive more than $4 million to support continuing MERS DNA vaccine technology research.
“Wistar is proud to be one of the first set of CEPI consortium members to receive funding that will accelerate development of vaccines for MERS and Lassa fever into efficacy trials in the next few years,” said Weiner. “In this day and age where diseases have no boarders, it is imperative that our vaccine arsenal is ready to react. The goal is for these vaccines to be available as soon as possible for global and on-site emergency deployment when needed.”…
DCVMN – Developing Country Vaccine Manufacturers Network [to 21 April 2018]
21 April 2018
Regional workshop: Optimization of vaccines’ manufacturing, containers and testing for global supply
7 May 2018 to 10 May 2018
Hyderabad / India
Industry Watch [to 21 April 2018]
:: Sanofi to invest €350 million in Canadian vaccine facility
April 12, 2018
Expansion demonstrates company’s commitment to innovation and leadership in global public health
New Toronto facility is one of the largest-ever investments by Sanofi in a single building
Significantly increases capacity to meet growing demand for pediatric and booster vaccine